SAVVAS NEOPHYTOU | PANMURE GORDON
It’s never a good sign when a pipeline asset is withdrawn, but this is financially fairly painless. It’s more evidence of AstraZenca’s struggle with its pipeline delivery.
MIKE MITCHELL | SEYMOUR PIERCE
It shows that AstraZenca’s strategy is higher risk than previously thought. Regulatory hurdles are hitting hard, and it has less experience in emerging markets than peers.
JEREMY BATSTONE-CARR | CHARLES STANLEY
The price drop since the Brintilla news was more sentiment-led than due to a change in earnings. But the decision raises questions about medium-term options.